How They Won It: Morgan Lewis Snags $577M Verdict For Asahi
When Switzerland-based Actelion Ltd. — accused of interfering with Asahi Kasei Pharma Corp.'s licensing agreement to develop cardiovascular drug Fasudil — began attacking the drug at trial by calling it ineffective...To view the full article, register now.
Already a subscriber? Click here to view full article